The head of the Montreal Heart Institute (ICM), Jean-Claude Tardif has revealed the preliminary results of his research ‘Colcorona’.

According to Jean-Claude Tardif, an anti-inflammatory drug known as colchicine can reduce the risk of complications and deaths caused by covid-19.

The study was experimented on 4,488 patients globally which generated convincing results as 20% reduction was evident in deaths and people getting admitted to hospital due to covid-19 through the usage of colchicine.

Colchicine was discovered 150 years ago. It is produced through a plant called Colchicum autumnale and known as potent anti-inflammatory drug. Colchicine is used to prevent gout attacks (sudden, severe pain in one or more joints caused by abnormally high levels of a substance called uric acid in the blood) in adults. Colchicine (Colcrys) is also used to relieve the pain of gout attacks when they occur.

Moreover, the white blood cells of covid contracted person develop exaggerated inflammatory response which causes complications. However, the study is aimed to produce a cure through interacting with the body with colchicine which may aid in reducing the complications.

While conversing about the study, Tardif spoke that the study publication would by released as fast as possible which will probably get reviewed by regulatory agencies, EMA (European Medicines Agency), Health Canada in Canada and the FDA in the US.